En Es
Categories

Industry News

Hologic Acquires European Molecular Diagnostic Company Diagenode

By Labmedica International staff writers
02 Mar 2021

IllustrationHologic, Inc. (Marlborough, MA, USA) has acquired Diagenode (Liège, Belgium), a developer and manufacturer of molecular diagnostic assays and epigenetics products, which is expected to diversify its diagnostic business across test menu, customer segments and geography.

Diagenode offers more than 30 real-time PCR (polymerase chain reaction) tests that are CE-marked for the detection of bacteria, parasites and viruses involved in sexually transmitted infections, respiratory diseases, meningitis and gastroenteritis. Diagenode previously collaborated with Hologic to develop Panther Fusion assays for group B Streptococcus and Bordetella. Diagenode is also playing a leading role in epigenetics with a robust portfolio of devices, kits, reagents, antibodies and services to aid in the analysis of DNA and RNA.

“Acquiring Diagenode further strengthens our molecular diagnostics business by expanding our international capabilities, improving our regional time-to-market, and allowing us to offer a broader, more differentiated test menu,” said Jan Verstreken, Hologic’s group president, international. “Diagenode has been a great partner since 2016, helping us develop and manufacture PCR-based assays for Panther Fusion. Now we look forward to accelerating and broadening those efforts to benefit our customers and patients.”

“We are very pleased that the Diagenode team will become part of Hologic’s diagnostic business,” said Didier Allaer, Diagenode’s founder and chief executive officer. “Our businesses are highly complementary, and we are excited that Hologic’s commercial resources and leadership in molecular automation will enable us to offer our assay menu more broadly. Being part of Hologic will help scale our products to their full potential.”

“We are excited to put our strong cash flow to work to acquire Diagenode and further strengthen our diagnostics business, which has had tremendous momentum in the United States and internationally,” said Steve MacMillan, Hologic’s chairman, president and chief executive officer. “The acquisition is consistent with our tuck-in M&A strategy, leverages our automation capabilities, and provides attractive growth potential. And combined with our recent purchase of Biotheranostics, it enables us to continue strengthening our base diagnostics business to accelerate growth post-COVID.”

Related Links:
Hologic, Inc.
Diagenode




E-mail Print
FaceBook Twitter Google+ Linked in

Hologic

Designs and provides products for clinical laboratory and blood screening, including testing items for detection of human diseases, such as tuberculosis, strep throat, pneumonia, and sexually transmitted diseases, as well as for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) contamination of blood
More info

More articles about Hologic

20 Oct 2021
Hologic Acquires Bolder Surgical to Expand Surgical Franchise
Hologic, Inc. (Marlborough, MA, USA) is set to acquire Bolder Surgical (Louisville, CO, USA; www.boldersurgical.com), a provider of advanced energy vessel sealing surgical devices, in a deal that will expand its surgical franchise.
Read More
24 Jun 2021
Hologic Completes Acquisition of Mobidiag
Hologic, Inc. (Marlborough, MA, USA) has completed its previously announced acquisition of Mobidiag Ltd. (Espoo, Finland), an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately USD 808 million.
Read More
04 Feb 2021
Hologic Partners with Google Cloud to Focus on AI and Machine Learning for Advancing Digital Diagnostic Capabilities
Hologic, Inc. (Marlborough, MA, USA) and Google Cloud have entered into a new agreement to focus on enhancing artificial intelligence (AI) and machine learning (ML) to bring about breakthrough results in cervical cancer screening.
Read More
07 Jan 2021
Hologic to Acquire Diagnostic Tests Provider Biotheranostics
Hologic, Inc. (Marlborough, MA, USA) has agreed to acquire Biotheranostics, Inc. (San Diego, CA, USA), a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately USD 230 million.
Read More
05 Jan 2021
Hologic Acquires SOMATEX Medical Technologies
Hologic, Inc. (Marlborough, MA, USA) has completed the acquisition of SOMATEX Medical Technologies GmbH (Berlin, Germany), a leader in biopsy site markers and localization technologies, for approximately USD 64 million.
Read More
02 Dec 2020
Hologic Receives FDA Clearance for Genius AI Detection Technology for Early Breast Cancer Detection
Hologic, Inc. (Marlborough, MA, USA) has received US Food and Drug Administration (FDA) clearance for its Genius AI Detection technology, a new deep learning-based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images.
Read More
20 Aug 2020
Hologic Showcased Latest Advances at Virtual ECR Congress 2020
Hologic, Inc. (Marlborough, MA, USA) showcased its latest advances and shared its new innovations on its virtual booth at the online ECR 2020 event held on July 15-21.
Read More
15 Dec 2016
Hologic to Sell Blood-Screening Business to Grifols for USD 1.85 Billion
US medical device maker Hologic, Inc. has agreed to sell off its share of the Procleix blood-screening business to long-time partner, Grifols SA, for USD 1.85 billion in cash.
Read More

Additional news

05 Aug 2022
Bio-Rad Acquires Curiosity Diagnostics from Scope Fluidics
Bio-Rad Laboratories (Hercules, CA, USA) has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (Warsaw, Poland) for a total consideration of up to USD 170 million, consisting of approximately USD 100 million in cash, and up to USD 70 million in future milestone payments.
Read More
04 Aug 2022
Capsule Endoscopy System Market Driven by Rising Preference for Minimally Invasive Screening Procedure
The global capsule endoscopy system market is expanding at a rapid pace due to the rising demand for the procedure using minimally invasive diagnostic techniques, increase in the introduction of technologically advanced capsules, growth in the geriatric population, and rising prevalence of cancer around the world.
Read More
02 Aug 2022
PerkinElmer Divests Other Businesses to Focus on Life Sciences and Diagnostics
PerkinElmer, Inc. (Waltham, MA; USA) has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital (New York, NY, USA) for total consideration of USD 2.45 billion in cash.
Read More
31 Jul 2022
Labcorp to Spin Off Clinical Development Business
LabCorp Diagnostics (Burlington, NC, USA) has announced that its board of directors has authorized the company to pursue a spin-off of its wholly owned Clinical Development business to shareholders through a tax-free transaction.
Read More
31 Jul 2022
IFCC Celebrates 70 Years of Advancing Science of Laboratory Medicine and In Vitro Diagnostics
The IFCC is celebrating 70 years (1952 – 2022) of enormous achievements that have been extraordinary and impressive, contributing to its mission of “Advancing excellence in laboratory medicine for better healthcare worldwide”.
Read More
27 Jul 2022
Medlab Asia and Asia Health to Host First-Ever Live, In-Person Event in Thailand
Informa Markets (London, UK), in partnership with Impact Muang Thong Thani (Nonthaburi, Thailand), have confirmed that Medlab Asia and Asia Health will take place in Thailand for the first time when the co-located events return live and in-person at the Impact Exhibition Center, Bangkok, from 19-21 October 2022.
Read More
25 Jul 2022
Registration Opens for RSNA 2022
Registration is now open for the Radiological Society of North America’s (RSNA, Oak Brook, IL, USA) 108th Scientific Assembly and Annual Meeting to be held at McCormick Place Chicago, Nov. 27 – Dec. 1, 2022.
Read More
25 Jul 2022
Bioperfectus and ELITechGroup Collaborate for Monkeypox Virus Testing Across Europe
Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China) and ELITechGroup S.p.A. (Puteaux, France) have entered into a strategic partnership for monkeypox virus testing across Europe.
Read More
20 Jul 2022
GE's Healthcare Business to Be Named GE HealthCare
GE (Boston, MA, USA) has announced that GE HealthCare will be the name of its healthcare business following its planned separation into three industry-leading, global, investment-grade public companies.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions